Amalgamated Bank Has $3.02 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Amalgamated Bank raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 119.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,033 shares of the medical research company's stock after acquiring an additional 4,921 shares during the period. Amalgamated Bank's holdings in Bio-Rad Laboratories were worth $3,022,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. UMB Bank n.a. boosted its position in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after buying an additional 45 shares during the period. Capital Advisors Ltd. LLC boosted its position in shares of Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after buying an additional 62 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Bio-Rad Laboratories during the first quarter worth approximately $51,000. Headlands Technologies LLC acquired a new position in shares of Bio-Rad Laboratories during the second quarter worth approximately $51,000. Finally, Quarry LP acquired a new position in shares of Bio-Rad Laboratories during the second quarter worth approximately $59,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BIO shares. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price objective for the company. StockNews.com upgraded Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Citigroup upped their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada upped their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO traded down $3.28 during trading on Monday, hitting $365.97. The company had a trading volume of 173,346 shares, compared to its average volume of 247,142. The company has a market cap of $10.25 billion, a P/E ratio of -13.39 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The business's 50-day moving average is $339.08 and its 200 day moving average is $312.54. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same period in the previous year, the business earned $2.33 EPS. The company's revenue was up 2.8% on a year-over-year basis. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the company's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the company's stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares of the company's stock, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company's stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.